Drug-coated red blood cells destroy blood clots from within

Main Category: Public Health
Article Date: 12 Aug 2003 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The Trojan Clot-Buster: Drug-Coated Red Blood Cells Destroy Blood Clots From Within

Thrombosis - the formation of internal blood clots - is a common cause of complications and even death following surgery. To create a better means of preventing thrombosis, researchers at University of Pennsylvania School of Medicine coated red blood cells (RBCs) with tissue plasminogen activator (tPA), a clot-dissolving drug commonly used as an emergency treatment for stroke.

When given alone, tPA has a short life span in circulation and has the potential to cause serious bleeding as it diffuses out of the bloodstream. The RBC/tPA combo, however, lasts ten times longer in the bloodstream than free-floating tPA and decreases the likelihood of excess bleeding, according to a new study.

'The idea of coating red blood cells with tPA was to create a Trojan Horse, a vehicle for sneaking tPA into the bloodstream that could not only add to the drug's longevity, but would also allow it to be incorporated into a growing blood clot. RBC/tPA can dissolve blood clots from within,' said Vladimir R, Muzykantov, MD, PhD, associate professor in Penn's Department of Pharmacology and author of the study.

'Our research shows that the Trojan Horse approach converts tPA into a potent killer of nascent blood clots, one that would pose a much smaller risk of causing internal bleeding.'

In the August issue of Nature Biotechnology, Muzykantov and his colleagues demonstrate in animal models how the marriage of red blood cells and tPA has the potential of safely preventing thrombosis following surgery and as a therapeutic for victims of heart attack or stoke.

'If developed for humans, the RBC/tPA method could provide an ideal way of delivering clot-busting drugs, with fewer side effects,' said Muzykantov. 'In theory, patients could donate blood before surgery and receive their own cells bound to tPA following surgery, providing a safer alternative to blood-thinning medication.'

Research has shown that preventing thrombosis helps to reduce mortality and morbidity in many diseases.

Unfortunately, current clot-busting drugs have the tendency to cause excessive bleeding, either by causing bleeding outside of the blood vessels or by removing pre-existing and, perhaps, beneficial blood clots. According to the Penn researchers, RCB/tPA spares existing blood clots and is too large to cause damage outside of the bloodstream.

To coat red blood cells with tPA, Muzykantov and his colleagues capitalized on the 'stickiness' of streptavidin-biotin, a protein complex used in laboratories to study molecular interactions.

Streptavidin forms an incredibly tight bond to a tiny molecule called biotin, so the researchers 'biotinylated' tPA and RBCs and used streptavidin to link them together. According to the researchers, the technique may provide a safe way of extending the longevity and safety of drugs within the circulatory system.

'Red blood cells can travel hundreds of kilometers throughout the blood vessels during their 100-or so day life-span. That fact alone makes the idea of RBC-bound therapeutics very interesting,' said Muzykantov.

'Moreover, red blood cells are relatively large, which makes it very difficult for drugs bound to them to burrow their way out of the bloodstream where they could potentially do damage.'

PENN Medicine is a $2.2 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system).

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System consists of four hospitals (including its flagship Hospital of the University of Pennsylvania, consistently rated one of the nation's 'Honor Roll' hospitals by U.S. News & World Report), a faculty practice plan, a primary-care provider network, three multispecialty satellite facilities, and home health care and hospice.